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ABSTRACT
The understanding of the role of B cells in patients with solid tumors remains insufficient. We found that 
circulating B cells produced TNFα and/or IL-6, associated with unresponsiveness and poor overall survival of 
melanoma patients treated with anti-CTLA4 antibody. Transcriptome analysis of B cells from melanoma 
metastases showed enriched expression of inflammatory response genes. Publicly available single B cell data 
from the tumor microenvironment revealed a negative correlation between TNFα expression and response 
to immune checkpoint blockade. These findings suggest that B cells contribute to tumor growth via the 
production of inflammatory cytokines. Possibly, these B cells are different from tertiary lymphoid structure- 
associated B cells, which have been described to correlate with favorable clinical outcome of cancer patients. 
Further studies are required to identify and characterize B cell subsets and their functions promoting or 
counteracting tumor growth, with the aim to identify biomarkers and novel treatment targets.
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Tumor infiltrating B cells may be associated with favorable 
prognosis in cancer patients and mice .1–4 B cells can 
produce antibodies and cytokines and are able to present 
antigens to T cells .5 B cells with such properties are found 
within tertiary lymphoid structures (TLS). The presence of 
TLS in itself may also be associated with a favorable prog-
nosis .6 B cell zones can contain a germinal center and 
support the generation of memory B cells and B cell recep-
tor class switching .7,8 In patients with lung cancer or 
melanoma, all common B cell subsets were observed, 
namely naïve and unswitched/switched memory B cells, 
and plasma cells .8,9 Activated B cells were able in vitro to 
present antigens from melanoma lysates to T cells and 
efficiently activate them .10,11 Higher clonality of CD4+ 
T cells was observed in lung cancer patients with TLS 
present in the tumor containing B cells continuously pre-
senting antigens .12 B cells were found to cross-present 30- 
mer peptides derived from the NY-ESO-1 antigen on 
MHC-I molecules to cytotoxic T lymphocytes in vitro .13 
It is thus important to consider potential contributions that 
B cells may provide in support of anti-tumor immune 
responses.
However, B cells may also promote tumor growth. They 
can produce IL-10 and/or TGFβ, which inhibit anti-tumor 
immune responses. Such B cells may be termed “regula-
tory B cells”. Unfortunately, no phenotypical markers are 
available for their identification, such that functional ana-
lyzes are necessary which represent additional methodolo-
gical challenges .14–18 B cells have been observed in the 
TME, inhibiting the conversion of cold to hot tumors by 
using intratumoral vaccination .19 One study showed that 
a partial depletion of B cells using an anti-CD20 antibody 
(Rituximab) in colorectal patients led to a reduction in 
tumor burden in 50% of patients .20 In metastatic mela-
noma this approach led to a decrease in tumor-associated 
inflammation .21 The tumor promoting roles of B cells 
may be associated with their implications in chronic 
inflammation and/or T cell suppression. Indeed, B cells 
have been shown to induce a chronically inflamed tumor 
microenvironment (TME) via the production of cytokines 
or the generation of immune complexes .21–23
Here we investigated phenotype and functionality of 
B cells from melanoma patients who received different 
therapies: 1) early stage patients (stage I/II) who were 
treated with virus-like particle vaccines24 , 2) advanced 
disease (stage III/IV) patients who were vaccinated with 
Melan-A peptide and adjuvants ;25 and stage IV patients 
treated with the α-CTLA4 blocking antibody Ipilimumab .26 
We found that Ipilimumab non-responders had higher fre-
quencies of TNFα and IL-6 producing peripheral B cells at 
baseline. Evidence for inflammatory cytokine producing 
B cells was also found in the other patient’s B cells from 
blood and tumors.
CONTACT Daniel E. Speiser doc@dspeiser.ch Clinical Tumor Biology & Immunotherapy Group, Department of Oncology, University of Lausanne, Epalinges, 
Switzerland.
Supplemental data for this article can be accessed on the publisher’s website.
ONCOIMMUNOLOGY                                        
2021, VOL. 10, NO. 1, e1873585 (11 pages) 
https://doi.org/10.1080/2162402X.2021.1873585
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits 
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Materials and methods
Melanoma patients
Blood was obtained from melanoma patients included into 
two interventional clinical trials (LUD00-018, ClinicalTrials. 
gov NCT00112229 and CYT004-MelQbG10 04, 
NCT00306566) and one observational study (Ethics 
Committee number: 400/11). The patients included are 
hereby referred to as cohort 1 (Supplementary table 1). 
Patients from the observational study (400/11) were 
selected and studied separately and in more detail in cohort 
2 (Supplementary table 2). Patients were enrolled upon 
written informed consent. Eligibility criteria and study 
design has been previously described .24–26 The studies 
were designed, approved and conducted according to rele-
vant regulatory standards approved by the Ethics 
Commission for Clinical Research of the Faculty of 
Medicine and University of Lausanne (Lausanne, 
Switzerland), Swissmedic (Swiss Agency for Therapeutic 
Product) and the Protocol Review Committee of the 
Ludwig Institute for Cancer Research (New York). Only 
baseline samples from before the trial treatment were used 
in this study. While patient samples were directly derived 
from venous blood samples, control PBMCs from healthy 
donors were isolated from blood concentrates obtained 
from the Blood Transfusion Center, Epalinges, Switzerland.
Human melanoma tissue specimens used for RNA 
sequencing and paired PBMC samples were collected in 
the framework of the observational study 87/06, approved 
by the Ethics Committee for Clinical Research of the 
Faculty of Biology and Medicine of the University of 
Lausanne. This is hereafter referred to as cohort 3 
(Supplementary table 3).
The tissue and paired PBMC samples used for the flow 
cytometric analysis were collected prior to scheduled sur-
gery as part of oncological treatment upon written 
informed consent, hereafter referred to as cohort 4 
(Supplementary table 4).
Human cell preparation and flow cytometry
Patient or healthy donor PBMCs were isolated from whole 
blood cells by Lymphoprep (Axis-Shield) centrifugation 
gradient and cryopreserved in liquid nitrogen. Frozen 
PBMCs were thawed in a water bath at 37°C. Cells were 
kept overnight at 37°C and 5% CO2 in RPMI (Gibco), 10% 
FSC (Gibco) and 100 U/ml IL-2 (Proleukin). Cells were 
then stimulated for 14 hours with 3 µg/ml CpG 7909 (PF- 
3512676 provided by Pfizer and Coley Pharmaceutical 
Group, Wellesley MA), after which 50 ng/ml PMA 
(Sigma-Aldrich) and 500 ng/ml Ionomycin (Thermo 
Fischer) were added. After another two hours 2 nM 
Monensin (Sigma-Aldrich) and 10 µg/ml Brefeldin 
A (Sigma-Aldrich) were added for another 4 hours. 
Control samples were kept in RPMI with 10% FSC. 
Monensin and Brefeldin A were added at the same time 
point as their stimulated counterpart.
The first step in the staining for flow cytometry analysis was 
the blocking of the Fc-receptor to avoid unspecific staining using 
an Fc-blocking reagent (Miltenyi, 130–059-901). The following 
antibodies were used for the phenotyping and functional char-
acterization of B cells from PBMCs and human melanoma tissue 
specimens, including the extracellular antibodies against: CD3 
(BD Biosciences Cat# 557832, RRID:AB_396890), CD3 (BD 
Biosciences Cat# 562994, RRID:AB_2737938), CD4 
(BioLegend Cat# 317436, RRID:AB_2563050), CD4 (BD 
Biosciences Cat# 562970, RRID:AB_2744424), CD8 
(BioLegend Cat# 344732, RRID:AB_2564624), CD8 (Beckman 
Coulter Cat# 737659, RRID:AB_2751015), CD8 (Beckman 
Coulter Cat# 737661, RRID:AB_1575980), CD14 (Beckman 
Coulter Cat# B01175, RRID:AB_2728099), CD19 (BioLegend 
Cat# 302208, RRID:AB_314238), CD27 (Thermo Fisher 
Scientific Cat# 61–0279-42, RRID:AB_2574546), CD5 
(Miltenyi Biotec Cat# 130–099-972, RRID:AB_2660340), CD38 
(Thermo Fisher Scientific Cat# 56–0389-42, RRID: 
AB_10804040), IgD (BD Biosciences Cat# 555778, RRID: 
AB_396113), CD126 (IL6-R) (BD Biosciences Cat# 551850, 
RRID:AB_394271) and PD-1 (BioLegend Cat# 329920, RRID: 
AB_10960742). After staining with extracellular antibodies, 
a live/dead staining (LIVE/DEAD™ Fixable Near-IR Dead Cell 
Thermo Fisher Scientific Cat# L-34975) was performed. Cells 
were fixed at RT during 30 minutes (FoxP3 intracellular staining 
kit, eBioscience). Intracellular staining was performed at room 
temperature (RT) during 30 minutes in FoxP3 intracellular 
staining kit permeabilisation buffer (eBioscience). Antibodies 
used for intracellular staining include: T-bet (BD Biosciences 
Cat# 562467, RRID:AB_2737621), IL-2 (BD Biosciences Cat# 
554565, RRID:AB_395482), IL-2 (BioLegend Cat# 500332, 
RRID:AB_2563877), IL-6 (BioLegend Cat# 501106, RRID: 
AB_315154), IL-10 (BioLegend Cat# 506804, RRID: 
AB_315454), IFNγ (BD Biosciences Cat# 557844, RRID: 
AB_396894), TNFα (BD Biosciences Cat# 557996, RRID: 
AB_396978), LTα (Thermo Fisher Scientific Cat# BMS105FI, 
RRID:AB_10598519) and IDO (a kind gift of Prof. Van den 
Eynde, Ludwig Institute for Cancer Research Brussels).
Cells were acquired using the Gallios flow cytometer or the 
CytoFLEX S (Beckman Coulter) and analyzed using FlowJo 
10.4.2 (FlowJo LCC).
Cell sorting and RNA sequencing
Tumor-infiltrating lymphocytes were prepared after finely 
mincing surgery specimens to yield a single cell suspension, 
which was cryopreserved on the same day as the surgery 
was performed. In short, cells were thawed and rested 
overnight in RPMI and FCS. B cells were sorted based on 
the expression of CD19 (Beckman Coulter Cat# A96418, 
RRID:AB_2728101) and CD45 (Biolegend Cat# 304012, 
RRID: AB_314400), only in case of tumor material, using 
the Astrios (BD Bioscience). Cells were sorted directly into 
RNA later (Invitrogen, AM7020) to conserve RNA upon 
cryopreservation at −80°C. RNA was extracted using the 
RNeasy Plus Micro kit (Qiagen, 74034) following the man-
ufacturer’s protocol. Quality of RNA was tested using 
a fragment analyzer (Advanced Analytical). Total RNA 
from all samples used for sequencing had an RQN ≥ 7. 
Libraries were obtained using the Clontech SMART-Seq v4 
(Takara). Single-end sequencing (100bp) was performed 
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using an Illumina HiSeq 2500 sequencer. These last two 
steps were performed at the Lausanne Genomics 
Technologies Facility (UNIL, Lausanne).
Transcript quantification was performed using Kallisto .27 In 
brief, target transcript sequences were obtained from ENSEMBL 
(GRCh38.p12), and the abundance of transcripts was quantified 
using Kallisto 0.44.0 with sequence-based bias correction. All other 
parameters were set to default when running Kallisto. Kallisto’s 
transcript-level estimates were further summarized at the gene- 
level using tximport 1.8.0 .28 For downstream analyses, lowly abun-
dant genes were filtered out, library size normalization and variance 
stabilization were performed using the regularized log transforma-
tion from DESeq2 1.22.0, 29 and unwanted variation was estimated 
and regressed out using SVA 3.30.0 .30 ENSEMBL gene ids were 
converted to gene symbol using org.Hs.eg.db 3.8.2 .31 If a gene 
symbol was associated with more than one ENSEMBL id, the 
ENSEMBL id with maximum variance was retained using the 
collapseRows functionality within the WGCNA R package .32 
Differential expression analysis was performed using limma 3.38.1 
from Bioconductor .33 Significant genes were identified using an 
adjusted p-value of 0.05 and log2FoldChange of 1. Gene Set 
Enrichment Analysis (GSEA) was performed using fgsea 1.8.0 
package from Bioconductor with limma’s t-statistic as gene-level 
statistic .34 Signaling pathways analyzed by GSEA were obtained 
from the Hallmark gene sets of the MSigDB .35 Heatmap was 
generated using the pheatmap R Package, 36 with clustering distance 
and method set to Euclidean and ward.D2, respectively. Volcano 
plots were generated using the ggrepel R package .37 Both raw and 
processed RNA-seq data have been deposited to Gene Expression 
Omnibus and will be accessible under accession number 
GSE157236.
To investigate differences in the expression of IDO1, 
CSF2, TNF, IL-6, IL-10, IL-2 and LTA in B cells associated 
with response status (responsive or non-responsive), we 
used the processed single cell RNA sequencing data 
reported by Sade-Feldman et al, 1 consisting of the expres-
sion profiles of 16,291 immune cells from 48 tumor sam-
ples of melanoma patients treated with checkpoint 
inhibitors. We selected the expression profile of 1,379 
cells classified as B cells according to the unsupervised 
clustering of CD45+ cells reported in the study. Then, 
we used the ‘glmmTMB’ R package to fit a zero inflated 
generalized linear mixed model to these profiles, setting 
response status as fixed effects and patient as a random 
effect .38 To obtain the distributions of mean gene expres-
sion by fixed effect level, we used the ‘emmeans’ 
R package, which estimates marginal means based on the 
predictions of the fitted model .39
Statistics and analysis
Significance of 2-group comparisons was assessed using the 
Mann–Whitney test, whereas multi-group comparisons were 
achieved using the Kruskal-Wallis test, within the GraphPad 
Prism 8 software. Analysis of co-expression of cytokines was 
performed using spice version 5.1 .40 Overall survival (OS) was 
defined as the time between sampling and latest follow-up and 
death. The significance of Kaplan-Meier survival analysis was 
assessed by the Log-rank test (within GraphPad Prism 8).
Results
Circulating B cells from melanoma patients show different 
frequencies, differentiation and functionality depending 
on disease stage
We first focused on B cells and their subsets from blood 
because of their easy accessibility and high prevalence, allowing 
to characterize patient’s B cells both phenotypically and func-
tionally. As we were primarily interested in prognosis and 
treatment prediction, we used baseline samples and did not 
analyze post-treatment specimens. Detailed information of the 
patients is provided in Supplementary table 1. B cells were 
identified as CD19 positive and their subsets like naïve, 
unswitched memory and switched memory B cells as 
IgD+CD27−, IgD+CD27+ and IgD−CD27+, respectively 
(Figure 1(a)). Looking at the different subsets, we observed 
a decrease in B cell frequencies in stage IV patients (cohort 1, 
as described in Materials & Methods) compared to healthy 
donors (Figure 1(b)). Analyzing B cell subsets, we observed 
a difference in unswitched memory B cells, with higher fre-
quencies in stage I/II compared to stage III and IV patients 
(Figure 1(c)). An inverse association could be observed in naïve 
B cells. Here we saw a significant increase in frequencies in 
stage III and IV patients compared to stage I patients (Figure 1 
(c)). Phenotypically, we found an increased frequency of IL-6 
receptor expression by B cells from stage IV patients compared 
to stage III patients (Figure 1(d)). We did not observe any 
significant differences in expression of CXCR3, Fas receptor, 
t-bet or PD-1 (Supplementary figure 1A). While we did not see 
significant differences depending on gender (data not shown), 
we could not exclude that the decrease in B cell frequencies in 
more advanced disease stages was biased by higher patient age. 
Indeed, B cell frequencies may be lower in the elderly .41,42 We 
found an inverse correlation between the age at diagnosis and 
the frequency of B cells (Supplementary figure 1B). Since we 
were not allowed to know the healthy donor’s age, we could not 
determine an eventual association with age. However, in agree-
ment with the decrease of B cells in the more advanced disease 
stages, we also found a negative correlation between B cell 
frequencies and the LDH values of the same patient, support-
ing the notion that B cell frequencies decrease with a higher 
disease burden (Supplementary figure 1B).
Since only little is known about B cell functionality in 
cancer, we stimulated B cells and analyzed the production of 
GMCSF, IL-2, IL-6, TNFα, LTα and IL-10. We found no sig-
nificant differences between patients and healthy donors, 
except a reduced TNFα production in stage III patients when 
compared to stage I/II patients (Figure 1(d)). Together, these 
findings show that B cells from melanoma patients are gener-
ally capable of producing cytokines.
Inflammatory cytokine production by circulating B cells 
correlates with non-responsiveness and short survival of 
patients treated with anti-CTLA4
Treatment with immune checkpoint blockade (ICB) provides 
clinical benefit in significant fractions of patients .43 To search 
for correlations of B cell characteristics with responsiveness to 
Ipilimumab (anti-CTLA4), we compared B cells from patients 
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Figure 1. B cell frequency, differentiation, phenotype and functionality in peripheral blood of melanoma patients. (a). B cells were identified as CD19+ and subtyped for 
naïve (IgD+CD27−), unswitched memory (IgD+ CD27+) and switched memory (IgD− CD27+) B cells. (b). B cell frequencies in blood as measured by flow cytometry from 
healthy donors (n = 34) and patients (n = 56), patients were further subdivided based on stage, including stage I/II (n = 8), III (n = 21) and IV (n = 27). (c). B cell 
differentiation as measured by flow cytometry and represented as frequency of B cells shown as naïve, switched and unswitched memory cells. Frequencies were 
analyzed from healthy donors (n = 34) and patients (n = 56), patients were further subdivided based on stage, including stage I/II (n = 8), III (n = 21) and IV (n = 27). (d). 
B cell phenotypes and function, assessed by flow cytometry, showing IL-6 R expressing B cells and analyzed from healthy donors (n = 21) and patients (n = 45), with 
stage I/II (n = 8), III (n = 13) and IV (n = 24). Cytokine production was assessed after stimulation with CpG (14 hours) and supplementary addition of PMA and ionomycin 
for 4 hours by flow cytometry in samples from healthy donors (n = 21) and patients (n = 45), with stage I/II (n = 8), III (n = 13) and IV (n = 24). For IL-10 the sample 
numbers were different: healthy donors (n = 33) and patients (n = 49), with stage I/II (n = 8), III (n = 15) and IV (n = 26). * p < .05, ** p < .01, *** p < .001 as determined 
by Kurskal-Wallis test.
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responding positively to Ipilimumab with the ones showing no 
benefit (cohort 2; Supplementary table 2).
Consistent with our results in cohort 1, we found that the 
frequencies of circulating B cells were decreased in the patients 
of cohort 2 at baseline (Figure 2(a)). The differentiation stages 
were similar as in healthy donors (Figure 2(a)). However, the 
patient’s B cells showed increased expression of CXCR3, Fas 
receptor and IL-6 receptor (Figure 2(b)). We did not find any 
significant differences in PD-1, t-bet or cytokine expression in 
comparison to healthy donors (Supplementary figure 2A). 
Significantly higher expression of Fas receptor or IL-6 receptor 
on patient’s B cells seems to indicate activated B cells, traffick-
ing to the site of inflammation as suggested by a higher pre-
sence of the chemokine receptor CXCR3 on the patient’s B cell 
surface.
We analyzed associations between B cell frequency, pheno-
type and functionality with response to ICB. We discovered 
that peripheral B cells from patients not responding to treat-
ment exhibited a higher expression of IL-6 R and had a higher 
frequency of B cells producing TNFα and IL-6. We also 
observed a trend for increased LTα expression (Figure 2(c)). 
Additionally, we found a positive trend, albeit not significant, 
for higher IL-2 production by B cells from responding patients 
(Figure 2(c)). We did not see significant differences between 
responders and non-responders when looking at frequencies of 
B cells subsets and expression of CXCR3, PD-1, Fas receptor, 
IL-10 and GMCSF (Supplementary figure 2B). Additionally, we 
did not find any significant differences between the numbers of 
B cells and their subsets in responder or non-responder 
patients (Supplementary figure 2B). Together, our data show 
that inflammatory cytokine producing B cells were more pre-
valent in non-responder patients. Interestingly, responder 
patients showed a trend for more IL-2 production (Figure 2 
(d)), a cytokine that supports T cell responses. Finally, we 
found negative correlations of IL-6 and TNFα levels with over-
all patient survival (Figure 2(d)). Thus, inflammatory B cells, 
especially producing IL-6 and TNFα, were negatively asso-
ciated with clinical outcome and could therefore be considered 
as potential biomarkers.
B cells from the TME show enriched expression of 
inflammatory and proliferative genes
Besides the results of circulating B cells that potentially reflect 
systemic immune reactions, we analyzed B cells from the TME. 
To our knowledge, sorted B cells from the TME have not been 
profiled to this date. Therefore, we sorted and sequenced B cells 
from melanoma metastases (n = 5), in parallel with B cells from 
blood of autologous stage III/IV melanoma patients (n = 5) and 
healthy donors (n = 4). Clinical data from the corresponding 
patients (cohort 3) are shown in Supplementary table 3.
We performed paired comparison of TME B cells with 
autologous blood B cells from the same 5 melanoma 
patients. The first principle component of our PCA ana-
lysis shows that samples segregate based on the origin of 
the sample (blood or TME) and not per patient (Figure 3 
(a)). 91 genes were differentially over-expressed in tumors 
compared to blood based on an adjusted p-value of 0.05 
and a log fold change of 1. The most interesting hits are 
indicated on a volcano plot (Figure 3(b)). The significantly 
differentially expressed genes are listed in Supplementary 
table 5. GSEA shows the presence of some important 
hallmarks, like Myc targets and IFN α/γ response as well 
as a downregulation of TGF-β signaling (Figure 3(c)).
Some of the differences may be due to the fact that we 
compared cells from tissue versus blood samples. To further 
focus on disease specific properties, we compared blood B cells 
from patients with blood B cells from healthy donors. Based on 
PCA analysis, we found that patient samples cluster together 
and away from healthy donor samples (Figure 3(d)). We found 
49 genes that were differentially over-expressed with an 
adjusted p-value smaller than 0.05 and a log fold change bigger 
than 1 (Figure 3(e)). A full list of these genes is provided in 
Supplementary table 6. GSEA analysis shows various enrich-
ments such as of complement and inflammatory response 
genes (figure 3(f)).
Venn analysis of the overlap between over and under- 
expressed B cell genes shows that two genes were commonly 
downregulated in patient blood versus healthy donor blood 
and in the TME versus patient blood (Figure 3(g)). Seven genes 
were commonly upregulated, including the costimulatory 
molecule CD86 and the IL-2 receptor beta-chain (Figure 3(h)).
Thus, even though tissue specific effects may play a role, we 
find increased expression of inflammatory and IFNγ/α 
response genes, suggesting that B cells are active and probably 
producing cytokines. An inflammatory profile was also found 
in circulating B cells of the non-responding cohort 3 patients 
by flow cytometry. Therefore, we found that both B cells from 
the TME and peripheral blood showed inflammatory 
properties.
B cells from the TME are functional and their TNFα 
production correlates with response to ICB treatment 
failure
In order to determine whether we can find further correla-
tions between inflammatory B cells and outcome to ICB 
treatment, we used the publicly available single cell RNA 
sequencing dataset published by Sade-Feldman et al .1 We 
investigated B cell functionality genes, as previously ana-
lyzed, like GMCSF, TNFα, LTα, IL-6, IL-2 and IL-10. We 
found that TNFα correlated with non-response and IL-2 
with response to ICB treatment (Figure 4(a)). Most of these 
patients were treated with anti-PD-1 antibodies (i.e. 35 
anti-PD-1, 11 anti-CTLA4 + PD-1, and 2 anti-CTLA4) .1 
Therefore, also within the TME, TNFα producing B cells 
negatively correlated with immunotherapy outcome.
Based on these mRNA data, we performed flow cytometric 
analyzes to determine cytokine production at the protein level 
by TME derived B cells from cohort 4 patients, as well as paired 
blood B cells. Clinical data of the patients included in this 
cohort is shown in Supplementary table 4. We confirmed the 
presence of naïve and memory (unswitched and switched) 
B cell subsets (Supplementary figure 3A). Moreover, B cells 
from the TME were capable of producing cytokines like 
GMCSF, IL-2, IL-6, LTα and TNFα. The B cells from the 
TME expressed inflammatory cytokines, although in part at 
lower levels than circulating B cells (Supplementary figure 3B). 
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Co-expression of cytokines showed that almost all peripheral 
B cells from healthy donors produced at least one of the 
analyzed cytokines. While single cytokine producers 
dominated, some B cells showed simultaneous production of 
TNFα and IL-6 (Figure 4(b)). In patients, the frequencies of 
functional B cells were lower, but many B cells were 
Figure 2. Circulating B cell frequency, differentiation, phenotype and response to anti-CTLA4 therapy in melanoma patients. (a). B cell frequency and differentiation as 
measured by flow cytometry including naïve, unswitched and switched memory B cells in healthy donors (n = 34) and patients (n = 21). (b). Phenotypical markers as 
assessed by flow cytometry including Fas receptor (CD95) and IL-6 receptor from healthy donors (n = 21) and patients (n = 22) as well as CXCR3 from healthy donors 
(n = 17) and patients (n = 14). (c). IL-6 receptor and cytokine expressing B cells in patients. They were defined as responders (R) (n = 8) when they had complete 
response, dissociated disease [at the same time presence of progression of some lesion(s) and of regression of other lesion(s)] or partial response. Non-responsive 
patients (NR) (n = 14) were defined when they had progressive disease. (d). Kaplan-Meier curves of overall survival of patients with lower (blue) or higher (red) 
frequencies of TNFα+ or IL-6+ B cells than the median. * p < .05, ** p < .01, *** p < .001 as determined by Mann-Whitney test.
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nevertheless capable of producing TNFα, IL-6, LTα and/or 
GMCSF (Figure 4(b)). Larger numbers of tumor biopsies 
would be required in order to confirm by flow cytometry that 
patients with weaker inflammatory cytokine production by 
their B cells have a better clinical outcome, as we found with 
mRNA data. Moreover, more research is required to distin-
guish inflammatory B cells from B cells within the TLS that 
appear to have anti-tumorigenic roles.
Discussion
B cells make up an important part of the adaptive immune 
system. Their role and function in the immune response to 
cancer still remain unclear. We found that circulating 
B cells from melanoma patients are often functional, as 
they produce GMCSF, IL-2, IL-6, TNFα, LTα and IL-10. 
Furthermore, we observed a correlation between treatment 
failure to anti-CTLA4 therapy and inflammatory circulating 
Figure 3. RNA sequencing analysis of B cells sorted from the TME, patient’s blood and healthy donor’s blood. (a). PCA analysis of B cells from the TME (red) and from the 
patient’s blood (black). (b). Volcano plot representation of the differential gene expression in B cells from the TME to B cells from patient’s blood. Adjusted p-value cutoff 
is 0.05 and log2(fold change) of −1 and 1. Hits passing these thresholds are represented in blue. (c). Bar graph representation of statistically significant enriched gene 
sets in B cells from the tumor compared to B cells from the patient’s blood. (d). PCA analysis of B cells from patient’s blood (red) and from healthy donor blood (black). 
(e). Volcano plot representation of the differential gene expression from B cells from patient’s blood to B cells from healthy donor blood. Adjusted p-value cutoff is 0.05 
and log2(fold change) of −1 and 1. Hits passing these thresholds are represented in blue. (f). Bar graph representation of statistically significantly enriched gene sets in 
B cells from patient’s blood to B cells from healthy donor blood. (g). Venn diagram of up-and downregulated genes in B cells from patient’s blood compared to B cells 
from healthy donor’s blood as well as B cells from the tumor to B cells from the patient’s blood. Genes were considered significantly upregulated if the adjusted 
p-value<0.05 and log2(fold change)>1. Genes were considered significantly downregulated if the adjusted p-value<0.05 and log2(fold change)<-1. The total number of 
differently expressed genes is also indicated. H. Lists of up- and downregulated genes shown in Figure 3 G.
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B cells, and inverse correlations of B cells producing IL-6 
and TNFα with overall patient survival. IL-6 is able to 
inhibit apoptosis in cancer cells as well as to induce angio-
genesis. Its presence, as also measured in sera, is often 
associated with progression in melanoma .44 IL-6 also 
induces the transcription factor c-Maf in T cells which 
promotes CD4 Th17 cells and CD8 T cell exhaustion .45,46 
TNFα induces immune-regulatory genes in melanoma .47 
Even though TNFα is able to induce apoptosis in tumor 
cells, prolonged exposure may induce survival molecules 
like anti-apoptotic proteins, proangiogenic factors and 
metastasis markers .48
For profiling of cells from the TME, we performed RNA sequen-
cing of sorted B cells from melanoma tumors. We found enriched 
expression of IFNα/γ response genes as well as Myc target genes in 
B cells from the TME compared to autologous blood B cells, sug-
gesting that B cells are active and produce cytokines in tumors. 
Furthermore, enrichment of inflammatory response and comple-
ment genes were found in B cells from patients as compared to 
healthy donors, indicating that also at a systemic level B cells are 
impacted and activated. Finally, single cell RNA sequencing data 
analysis from B cells from the TME showed that TNFα producing 
B cells inversely correlated with ICB treatment outcome. Thus, also 
in the TME, inflammatory B cells may promote resistance to 
immunotherapy.
Sustained inflammation has been suggested as an emerging 
hallmark of cancer by Hanahan and Weinberg .49 Previous 
studies described a role for inflammatory B cells in cancer 
progression. For example, B cells form immune complexes 
that can regulate myeloid cell infiltration and chronic inflam-
mation, as shown in a murine squamous carcinoma model. 
Therapeutic depletion of B cells in this model led to an 
improved cytotoxic T cell response and improved response to 
chemotherapy .50,51
On the other hand, IL-2 transcripts in B cells correlated with 
treatment response, suggesting that these B cells could be 
involved in T cell activation, a role described for B cells present 
in TLS, a privileged site for antigen presentation to T cells by 
Figure 4. A. Distribution of mean gene expression in 1,379 single B cells, by response status (444 cells come from non-responders (NR) and 935 come from responders 
(R)). Mean expression values were estimated after fitting a zero inflated generalized linear mixed model to the expression profiles of B cells, setting response status as 
fixed effects and patient as a random effect. The bars represent the confidence intervals of the estimated means. B. Co-expression of cytokines as produced by B cells 
from respectively the peripheral blood of healthy donors (n = 3) or patients (n = 14), or the TME (n = 10).
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DCs, as well as a place for the formation of germinal centers 
leading to local antibody production in the B cell rich zone. 
The presence of TLS in different types of cancers is mostly 
described as a positive prognostic marker .52 Recent evidence 
shows a positive role for B cells in the TLS and its association 
with response to ICB. It seems that especially memory and 
plasma cells contribute to this mechanism .53 However, the 
functional mechanisms of these B cells remain to be fully 
elucidated.
While analyzing the B cell cluster from single cell RNA 
sequencing data of patients treated with ICB1 we found that 
TNFα transcripts negatively correlated with treatment failure. 
Even though B cells from the TME showed reduced activation 
levels as compared to B cells from blood of patients and healthy 
donors (at the protein level), they were still able to produce 
inflammatory cytokines. It may not be surprising that the 
cellular functions in the B cells of the TME were lower than 
in circulating cells, as similar findings were made for other cell 
types, particularly for T cells .54
Recent studies on B cells in cancer mostly focused on their 
anti-tumor associations and functions, which seem to be pri-
marily attributed to B cells found within TLS .53,55 
Additionally, two clinical trials have used Rituximab (anti- 
CD20 monoclonal antibody) in metastatic melanoma patients 
to target a rare population of CD20-expressing melanoma cells 
.56,57 The therapies also effectively depleted B cells from the 
periphery. Even though the clinical results are not conclusive 
due to the small patient numbers, it seems that depleting B cells 
did not worsen the clinical outcome. The question whether 
B cells can be safely targeted deserves more studies.
Specific cell surface markers would improve the distinction 
of the different B cell subsets, for further investigating their 
importance, their micro-anatomical location and interactions, 
and underlying mechanisms. Unfortunately, the surface mar-
kers tested in our study (IL-6 R, CD95, PD-1, CXCR3) did not 
correlate with the production of proinflammatory cytokines 
(IL-6, TNFα, LTα). Nevertheless, our findings on inflammatory 
B cells may be considered for ICB outcome prediction. Future 
studies may determine the functionality of inflammatory 
B cells in more detail to reach a thorough understanding of 
their roles in tumor immunology.
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